Loudon Investment Management LLC bought a new stake in Amgen Inc. (NASDAQ:AMGN) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 12,678 shares of the medical research company’s stock, valued at approximately $2,080,000. Amgen makes up approximately 1.6% of Loudon Investment Management LLC’s holdings, making the stock its 27th largest position.
A number of other hedge funds and other institutional investors have also recently modified their holdings of AMGN. Alpha Omega Wealth Management LLC increased its position in shares of Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock valued at $103,000 after buying an additional 100 shares in the last quarter. Jackson Grant Investment Advisers Inc. increased its position in shares of Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after buying an additional 4 shares in the last quarter. Thomas J. Herzfeld Advisors Inc. purchased a new position in shares of Amgen during the fourth quarter valued at $102,000. Signature Estate & Investment Advisors LLC increased its position in shares of Amgen by 13.6% in the first quarter. Signature Estate & Investment Advisors LLC now owns 794 shares of the medical research company’s stock valued at $130,000 after buying an additional 95 shares in the last quarter. Finally, Focused Wealth Management Inc increased its position in shares of Amgen by 248.0% in the fourth quarter. Focused Wealth Management Inc now owns 870 shares of the medical research company’s stock valued at $127,000 after buying an additional 620 shares in the last quarter. 78.80% of the stock is owned by institutional investors.
Amgen Inc. (NASDAQ AMGN) opened at 180.21 on Friday. Amgen Inc. has a 1-year low of $133.64 and a 1-year high of $184.21. The company has a market capitalization of $132.53 billion, a P/E ratio of 17.12 and a beta of 1.36. The stock’s 50 day moving average is $169.47 and its 200-day moving average is $165.39.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Wednesday, April 26th. The medical research company reported $3.15 EPS for the quarter, topping the consensus estimate of $3.00 by $0.15. Amgen had a net margin of 34.42% and a return on equity of 29.37%. The company had revenue of $5.46 billion during the quarter, compared to analysts’ expectations of $5.60 billion. During the same quarter in the previous year, the business posted $2.90 EPS. The firm’s revenue was down 1.1% on a year-over-year basis. On average, analysts expect that Amgen Inc. will post $12.47 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “12,678 Shares in Amgen Inc. (AMGN) Acquired by Loudon Investment Management LLC” was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://stocknewstimes.com/2017/07/22/12678-shares-in-amgen-inc-amgn-acquired-by-loudon-investment-management-llc.html.
Several research analysts recently weighed in on the stock. Mizuho set a $195.00 target price on shares of Amgen and gave the stock a “buy” rating in a report on Saturday, May 6th. UBS AG reiterated a “neutral” rating and issued a $174.00 price target (down previously from $175.00) on shares of Amgen in a research note on Monday, May 22nd. Jefferies Group LLC reiterated a “buy” rating and issued a $195.00 price target on shares of Amgen in a research note on Tuesday, July 11th. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $189.00 price target on shares of Amgen in a research note on Friday, July 14th. Finally, BMO Capital Markets reiterated a “buy” rating and issued a $198.00 price target (down previously from $200.00) on shares of Amgen in a research note on Monday, May 22nd. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, twelve have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $185.17.
In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of the business’s stock in a transaction that occurred on Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total transaction of $451,156.80. Following the completion of the transaction, the senior vice president now owns 24,214 shares in the company, valued at approximately $3,738,641.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.20% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
